Total Funding
39
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-14 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
238497
Hybrigenics offers a bioinformatics platforms to identify, validate, and inhibit protein interactions to develop therapeutics for cancer.
- Remi Delansorne: Chairman and CEO
Daan Ellens: Chairman of The Supervisory BoardPast Role: Rhein biotech NV, Chief Executive Officer
About the Company
Hybrigenics Pharma is a bio-pharmaceutical company with a focus on research and development of new targets and therapies against cancer.Hybrigenics Pharma has stopped the development of inecalcitol, a vitamin D receptor agonist.Hybrigenics Pharma's research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in
the recycling of onco-proteins and the potential activity of proprietary patented DUB inhibitors against various cancer indications.
